Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30528409 | 0.83 | KMO (0.39) | KMOALDH1A1SMN1; SMN2MAPK1GPR35 | |
| SCHEMBL9196203 | 0.83 | KMO (0.54) | KMOALDH1A1SMN1; SMN2MAPK1GPR35 | |
| Hydrochloric Acid SCHEMBL2192452 | 0.82 | KMO (0.53) | KMOALDH1A1SMN1; SMN2MAPK1GPR35 | |
| SCHEMBL31224327 | 0.79 | BAZ2B (0.47) | SMN1; SMN2S1PR2NPC1RAB9APOLB | |
| SCHEMBL3641920 | 0.79 | KDM4E (0.44) | ALDH1A1SMN1; SMN2MAPK1NPC1RAB9A | |
| SCHEMBL5683134 | 0.78 | LMNA (0.50) | KMOALDH1A1SMN1; SMN2MAPK1GPR35 | |
| SCHEMBL2823270 | 0.76 | CYP1A2 (0.51) | ALDH1A1SMN1; SMN2MAPK1S1PR2NPC1 | |
| SCHEMBL3055010 | 0.75 | LMNA (0.47) | KMOALDH1A1SMN1; SMN2MAPK1GPR35 | |
| SCHEMBL24739337 | 0.75 | NOS3 (0.38) | KMOSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL5850051 | 0.75 | POLB (0.45) | ALDH1A1SMN1; SMN2MAPK1GPR35S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4339193-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2024-03-20 | — | — | EP | disclosed |
| CN-113330009-B | Azacyclic compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2022237858-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-11-17 | — | — | WO | disclosed |
| CN-115340528-A | Compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-113330009-A | Nitrogen heterocyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| WO-2020182018-A1 | NITROGEN HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-09-17 | — | — | WO | disclosed |
| WO-2020182018-A1 | NITROGEN HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-09-17 | — | — | WO | disclosed |
| EP-3291817-B1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180280390-A1 | Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| CN-101910184-A | Solubility thiazole and pyridine | SIRTRIS PHARMACEUTICALS INC | 2010-12-08 | — | — | CN | disclosed |
| CN-101827845-A | Cgrp antagonists | BOEHRINGER INGELHEIM INT | 2010-09-08 | — | — | CN | disclosed |
| EP-2217606-A1 | SOLUBILIZED THIAZOLOPYRIDINES | Sirtris Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009050232-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050234-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-5324710-A | Sulfonated heterocyclic carboxamides and their use as herbicides, and growth regulators | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRT3, SIRT1, SIRT2 | KMO 634/4885ALDH1A1 778/4885SMN1; SMN2 1294/4885 |
| US-20180280390-A1 | Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors | PDE2A, PDE12, PDE7B | KMO 461/4885ALDH1A1 718/4885SMN1; SMN2 1516/4885 |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE7B | KMO 461/4885ALDH1A1 718/4885SMN1; SMN2 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.